Immunovant, Inc. (NASDAQ:IMVT) Receives $43.55 Consensus Target Price from Analysts
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy […]
Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy […]
